Krabbe disease is one of those lysosomal storage disorders that USMLE loves because it’s high-yield, pattern-recognition heavy, and hits multiple disciplines at once: biochem (enzyme), neuro (demyelination), path (globoid cells), and peds (early infantile decline). If you can quickly connect GALC deficiency → ↑ psychosine → oligodendrocyte toxicity → demyelination, you’re already ahead.
Where Krabbe Fits in the Big Picture (Step 1 framing)
Krabbe disease is a lysosomal sphingolipidosis (a subtype of lysosomal storage disease) that primarily causes central and peripheral demyelination due to impaired breakdown of galactocerebrosides.
High-yield classification:
- Lysosomal storage disease (not a glycogen storage disease)
- Sphingolipid metabolism disorder
- Leukodystrophy (white matter degeneration)
First Aid cross-reference: Look under Lysosomal Storage Diseases (often grouped with Tay-Sachs, Niemann-Pick, Gaucher, Fabry, Metachromatic leukodystrophy). Krabbe is the one with globoid cells + psychosine accumulation.
Definition (one-liner you should be able to say on test day)
Krabbe disease is an autosomal recessive lysosomal storage disorder caused by galactocerebrosidase (GALC) deficiency, leading to accumulation of psychosine and galactocerebroside, resulting in severe demyelination.
Pathophysiology: The “Why” Behind the Symptoms
The enzyme defect
- Enzyme: Galactocerebrosidase (GALC)
- Normal job: Degrades:
- Galactocerebroside (major myelin lipid)
- Psychosine (galactosylsphingosine)
The key toxic player: psychosine
- Psychosine accumulates when GALC is deficient
- Psychosine is directly toxic to oligodendrocytes and Schwann cells
- → CNS + PNS demyelination
- → rapid neurologic deterioration
Classic pathology: globoid cells
- Lipid-laden macrophages in white matter called globoid cells
- Think: macrophages “stuffed” with unmetabolized sphingolipids
Quick chain (memorize this)
AR inheritance → ↓ GALC → ↑ psychosine → oligodendrocyte death → demyelination → neurodegeneration
Clinical Presentation (the Step 1/2 pattern)
Most commonly presents as early infantile Krabbe (classic board style).
Typical onset
- Usually before 6 months (often 3–6 months)
Core features (high-yield)
- Developmental delay/regression
- Irritability (often prominent)
- Hypertonia/spasticity
- Peripheral neuropathy
- Seizures
- Vision loss (optic atrophy can occur)
- Feeding difficulties/failure to thrive
- Often progresses to decerebrate posturing and early death (classically by age 2)
“But what about hepatosplenomegaly?”
- Not a hallmark of Krabbe (more suggestive of Niemann-Pick, Gaucher)
- If a vignette emphasizes big HSM, reconsider your diagnosis.
Diagnosis (what they’ll ask you to pick)
Step-style diagnostic clues
- Infant with rapid neurodegeneration + demyelination
- Peripheral neuropathy (can help separate from some other leukodystrophies)
- Path shows globoid cells
- Labs show ↓ GALC activity
Confirmatory tests
- Enzyme assay: low GALC activity (leukocytes or fibroblasts)
- Genetic testing: GALC gene mutations
Supportive studies you might see in vignettes
- MRI brain: white matter abnormalities (leukodystrophy pattern)
- Nerve conduction studies: demyelinating neuropathy (slowed conduction)
Treatment (what’s realistic vs what’s board-relevant)
Disease-modifying option (key board point)
- Hematopoietic stem cell transplant (HSCT)
- Best if done pre-symptomatically or very early
- Concept: donor-derived cells can provide functional enzyme in CNS/PNS (partial correction)
Supportive care
- Seizure control
- Nutritional support
- Management of spasticity
- Palliative care for advanced disease
Step 2 mindset: Early recognition matters because HSCT has the greatest benefit before irreversible neurologic damage.
High-Yield Associations & Differentials (don’t miss these)
Krabbe vs Metachromatic Leukodystrophy (MLD)
Both are leukodystrophies with demyelination—classic test trap.
| Feature | Krabbe | Metachromatic Leukodystrophy (MLD) |
|---|---|---|
| Enzyme | Galactocerebrosidase (GALC) | Arylsulfatase A |
| Accumulates | Psychosine (toxic), galactocerebroside | Cerebroside sulfate |
| Path | Globoid cells | Metachromatic material (sulfatides) |
| Big concept | Psychosine kills oligodendrocytes | Sulfatide accumulation causes demyelination |
Krabbe vs Tay-Sachs / Niemann-Pick
- Tay-Sachs: Hexosaminidase A deficiency, cherry-red macula, no hepatosplenomegaly
- Niemann-Pick: Sphingomyelinase deficiency, hepatosplenomegaly, foam cells, cherry-red macula
- Krabbe: demyelination + globoid cells, psychosine, often peripheral neuropathy
First Aid–Style Memory Hooks (without the fluff)
The “3 Gs” for Krabbe
- GALC deficiency
- Globoid cells
- Galactocerebroside (and psychosine) accumulation
What they love to ask
- Inheritance: autosomal recessive
- Main toxicity: psychosine → oligodendrocyte death
- Big clinical theme: infantile-onset demyelination with rapid neurologic decline
Rapid-Fire USMLE High-Yield Facts (checklist)
- Autosomal recessive
- Enzyme: ↓ galactocerebrosidase (GALC)
- Accumulation: ↑ psychosine (high-yield toxin), ↑ galactocerebroside
- Pathology: globoid cells
- Clinical: irritability, developmental regression, hypertonia/spasticity, seizures, peripheral neuropathy, vision loss
- Diagnosis: low GALC enzyme activity ± genetic testing
- Treatment: HSCT early; otherwise supportive
Practice-Question Vignette (how it appears on exams)
A 4-month-old infant has progressive irritability, stiffness, and developmental regression. Exam shows hypertonia and diminished peripheral nerve conduction velocities. MRI shows diffuse white matter disease. Biopsy reveals multinucleated globoid cells.
Most likely enzyme deficiency? → Galactocerebrosidase (GALC)
Frequently Asked Questions
Why does GALC deficiency cause demyelination in Krabbe disease?
GALC deficiency causes demyelination because it leads to psychosine accumulation, and psychosine is directly toxic to oligodendrocytes and Schwann cells. GALC normally degrades galactocerebroside and psychosine. When the enzyme is deficient, psychosine builds up, damages myelin-producing cells in both the CNS and PNS, and produces rapid neurologic deterioration with central and peripheral demyelination.
How do you tell Krabbe disease from metachromatic leukodystrophy on Step 1?
The key distinction is that Krabbe disease has galactocerebrosidase deficiency with psychosine accumulation and globoid cells, whereas metachromatic leukodystrophy has arylsulfatase A deficiency with cerebroside sulfate accumulation. Both are leukodystrophies with demyelination, so the enzyme defect, accumulated substrate, and pathology are the highest-yield ways to separate them in a vignette.
What clinical clues point to Krabbe disease in an infant?
Classic Krabbe disease presents in early infancy, usually before 6 months, with rapid neurologic decline. High-yield clues include developmental delay or regression, prominent irritability, hypertonia or spasticity, peripheral neuropathy, seizures, vision loss, and feeding difficulties or failure to thrive. It can progress to decerebrate posturing and early death, making the pattern one of severe infantile neurodegeneration with demyelination.
How is Krabbe disease diagnosed?
Krabbe disease is diagnosed by showing low galactocerebrosidase activity and supported by characteristic clinical and pathologic findings. Step-style clues include an infant with rapid neurodegeneration, demyelination, peripheral neuropathy, and globoid cells on pathology. Confirmation is made with an enzyme assay showing decreased GALC activity, and genetic testing can identify mutations in the GALC gene.
What is the board-relevant treatment for Krabbe disease?
The key disease-modifying treatment is hematopoietic stem cell transplant, especially if it is done before symptoms begin or very early in the course. This matters because donor-derived cells can provide functional enzyme in the CNS and PNS, offering partial correction. Once irreversible neurologic damage has occurred, management is mainly supportive, including seizure control, nutritional support, spasticity treatment, and palliative care.